中国实用外科杂志2024，Vol.44Issue(9)：1021-1027,7.DOI:10.19538/j.cjps.issn1005-2208.2024.09.11
肝细胞癌免疫联合靶向治疗方案中的瓶颈与对策
Bottlenecks and countermeasures in immunotherapy combined with targeted therapy for hepatocellular carcinoma
摘要
Abstract
Hepatocellular carcinoma(HCC)is a common malignant tumor in China.The treatment of advanced HCC usually relies on systemic therapy.Immunotherapy combined with target therapy(combination therapy as short)shows significant advantages in advanced HCC treatment.Several regimens have passed phase Ⅲ trials and are widely used in real-world treatment.There are currently some bottlenecks in combination therapy for advanced HCC,such as the rising standard of clinical trials,the gap between trail design and clinical application,the increase in adverse events caused by target-immune synergization,the relatively high incidence of treatment resistance,and the high risk or lack of evidence of combination therapy in certain patient groups.To overcome these bottlenecks,possible means include finding new potential therapeutic targets,achieving precise patient selection through etiology and biomarkers,better understanding and managing the adverse events brought by the target-immune synergization,and further exploring the usage of combined or sequential therapeutic regimens.Multidisciplinary and multi-center cooperation will improve the theoretical and clinical experience of the combination therapy,and bring greater survival benefits to patients with advanced HCC.关键词
肝细胞癌/系统治疗/免疫治疗/靶向治疗/联合治疗Key words
hepatocellular carcinoma/systemic therapy/immunotherapy/target therapy/combination therapy分类
医药卫生引用本文复制引用
陈湘麒,张楠,赵海涛..肝细胞癌免疫联合靶向治疗方案中的瓶颈与对策[J].中国实用外科杂志,2024,44(9):1021-1027,7.基金项目
国家高层次人才特殊支持计划项目(万人计划) （万人计划）
中国医学科学院医学与健康科技创新工程2021年"揭榜挂帅"项目(No.2021-I2M-1-061,No.2021-I2M-1-003) （No.2021-I2M-1-061,No.2021-I2M-1-003）
北京协和医院中央高水平医院临床科研专项基金项目(No.2022-PUMCH-B-128) （No.2022-PUMCH-B-128）
中国医学科学院临床与转化医学研究专项项目(No.2022-I2M-C&T-A-00) （No.2022-I2M-C&T-A-00）
希思科-默沙东肿瘤研究基金项目(No.Y-MSDZD2021-0213,No.Y-HR2019-0239,No.Y-HR2020MS-0415,No.Y-HR2020QN-0414) （No.Y-MSDZD2021-0213,No.Y-HR2019-0239,No.Y-HR2020MS-0415,No.Y-HR2020QN-0414）
